The levels of miRNAs might be different between GC plasma and gastric mucosa. MiR-21 is overexpressed in various cancers, including breast cancer, lung cancer, colon cancer, and GC. Although Tsujiura et al reported that the plasma levels of miR-21 were significantly elevated in GC patients, its levels in plasma from GC patients at different TNM stags have not been identified. Increasing number of papers reported that circulating miRNAs can serve as noninvasive biomarkers for GC detection. Recently, Hanshao Liu reported that serum miR-378 was significantly elevated in the GC patients with TNM stage I, suggesting that this miRNA signature can serve as a novel noninvasive biomarker for early detection of GC. But the Hp infection status in the GC patients and healthy controls were not mentioned. It is well known that Hp infection is one of the major causes of GC, including gastric adenocarcinoma, gastric MALT lymphoma. If the plasma/ serum levels of the specific circulating miRNAs were only dysregulated in GC patients with Hp infection but not in those without, the miRNAs might serve as biomarkers for the detection of patients with Hp infection instead of the detection of patients with GC. In this study, although we analyzed the plasma levels of miR223, miR-21 and miR-218 in GC patients at different TNM stages, the number of early-stage GC samples was modest. The number of plasma miRNAs tested in training set was limited. In the future investigation, we may access more number of earlystage GC samples to evaluate the role of plasma miR-223, miR-21, miR-218 or other plasma miRNAs associated with GC in early detection of GC. For the purpose of searching effective blood-based biomarkers for GC detection to prolong the survival of patients with early GC, many researchers have focused on circulating miRNAs, which have recently been reported to serve as an effective and noninvasive biomarker for detecting various cancers or other diseases. Although the sensitivity and specificity of circulating miRNA biomarkers for GC detection are much Axitinib 319460-85-0 higher than that of the serum biomarkers currently used, it is a long way to go before circulating miRNAs as a clinical diagnosis are used to detect GC, because the levels of a circulating miRNA might be significantly higher or lower in various diseases. Future studies of circulating miRNA biomarkers may focus on combining the expression profiles of circulating miRNAs from all common diseases to obtain the specific biomarkers for unique disease detection. Although Jianning Song recommended miR-16 and miR-93 as suitable reference genes for serum miRNA analysis for GC patients and healthy controls, the sample size is modest. The normalization methods used to determine the levels of circulating miRNAs should be unified. In conclusion, we identified that three plasma miRNAs can potentially serve as novel noninvasive biomarkers for GC detection. Whether miR-223 and miR-21 have a capability to detect early-stage GC will be identified in future studies. Recent advances in lipidomic profiling have shown that specific fatty acid species in human plasma are associated with adiposity and lifestyle variables, such as smoking, physical activity and diet, while others correlate with hepatic and whole-body insulin sensitivity. Circulating palmitate is elevated in individuals with coronary heart disease and an increase in dietary intake thereof is associated with lower energy expenditure. It has previously been demonstrated by our group that palmitic acid in the phospholipid fraction of skeletal muscle is associated with increased adiposity in Pima Indians.